DexCom, Inc. (DXCM) Rating Reiterated by BMO Capital Markets
DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “buy” rating reissued by research analysts at BMO Capital Markets in a research report issued to clients and investors on Thursday. They presently have a $105.00 price objective on the medical device company’s stock. BMO Capital Markets’ target price would indicate a potential upside of 46.40% from the company’s previous close.
DXCM has been the topic of a number of other reports. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of DexCom in a research note on Wednesday, March 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 price target on shares of DexCom in a research note on Wednesday, June 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $78.00 price target on shares of DexCom in a research note on Monday, May 22nd. BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Finally, BTIG Research lowered shares of DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $89.47.
DexCom (NASDAQ DXCM) opened at 71.72 on Thursday. DexCom has a 12 month low of $57.68 and a 12 month high of $96.38. The stock has a 50 day moving average price of $71.68 and a 200 day moving average price of $74.65. The stock’s market capitalization is $6.19 billion.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. The firm had revenue of $142.30 million for the quarter, compared to analyst estimates of $143.94 million. DexCom had a negative net margin of 14.70% and a negative return on equity of 32.94%. Equities analysts predict that DexCom will post ($0.71) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/07/17/dexcom-inc-dxcm-rating-reiterated-by-bmo-capital-markets.html.
In other news, insider Terrance H. Gregg sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 20th. The shares were sold at an average price of $74.10, for a total transaction of $1,111,500.00. Following the completion of the sale, the insider now owns 454,559 shares in the company, valued at approximately $33,682,821.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total transaction of $113,375.50. The disclosure for this sale can be found here. Insiders sold a total of 53,063 shares of company stock worth $3,800,519 over the last three months. Corporate insiders own 1.70% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Eqis Capital Management Inc. increased its stake in shares of DexCom by 35.1% in the second quarter. Eqis Capital Management Inc. now owns 9,917 shares of the medical device company’s stock worth $725,000 after buying an additional 2,578 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in shares of DexCom by 508.8% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 13,722 shares of the medical device company’s stock worth $1,004,000 after buying an additional 11,468 shares in the last quarter. Chevy Chase Trust Holdings Inc. increased its stake in shares of DexCom by 10.4% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 46,889 shares of the medical device company’s stock worth $3,430,000 after buying an additional 4,399 shares in the last quarter. Bank of Montreal Can increased its stake in shares of DexCom by 69.2% in the second quarter. Bank of Montreal Can now owns 31,403 shares of the medical device company’s stock worth $2,296,000 after buying an additional 12,847 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of DexCom during the second quarter worth about $322,000.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.